IMROY Immuron Ltd featured news, full reports, and detailed charts
Immuron Ltd (IMROY/IMROY.PK) Wrap Up:
Immuron Limited, a biotechnology company, engages in the research and development of pharmaceutical products in Australia. It focuses on the use of polyclonal antibodies for the treatment and prevention of gastrointestinal, and infectious and immune-mediated diseases. The company?s products include Travelan for the prevention of traveller?s diarrhoea; BioGard, a Phase IV clinical trial product for the treatment of gastrointestinal inflammatory processes seen in persons with HIV/AIDS and chronic GI inflammatory diseases; Gastrogard-R for the prevention of diarrhoea due to rotavirus in at-risk children aged one month to three years; Anacrim, an oral BCP formulation for cancer patients to address side effects from cancer treatment; and Clostridium difficile for the prevention and treatment of C. difficile associated disease, including antibiotic associated diarrhoea. Its product in clinical trials includes Flubody, which provides immunity to an individual at risk of exposure to influenza virus infection. The company, formerly known as Anadis Limited, is based in Melbourne, Australia.Immuron Ltd (IMROY:OTC)
|
Market Cap
20.5M
|
Total Revenue
870.6K
|
|
|
EBITDA
2.4M
|
DILUTED EPS TTM
-0.02
|
|
|
P/E
--
|
P/S
14.8x
|
|
|
Return On Asset
-131.06
|
Return On Equity
-581.74
|
|
| K = Thousands M = Millions B = Billions | ||
IMROY Top Compensated Officers
Executives, Board Directors
Key developments for Immuron Ltd (IMROY)
Immuron Limited announced earnings results for the year ended June 30, 2009. For the quarter, the company reported total revenue of AUD 550,900 compared to AUD 319,400 for the same period last year. Pre-tax loss of AUD 2,625,000 compared to AUD 3,204,200 for the same period last year. Negative operating cash flow was AUD 2,072,100 compared to AUD 2,074,500 for the same period last year. Loss per share final reduced 31.2% from AUD 0.0279 to AUD 0.0192 for the same period last year.
Immuron Limited, Annual General Meeting, Nov 23, 2009, at 10:30 EAST-East Australian Standard GST. Location: Room 1, Level 2, RACV Club, 501 Bourke Street, Melbourne, Victoria, Australia. Agenda: To receive and consider the financial report of the company and the reports of the directors and auditor for the year ended June 30, 2009; to receive and adopt the remuneration report for the year ended June 30, 2009; to consider re-appointment of Mr. Arie Nudel as a director; to consider re-appointment of Professor Roy Robins-Browne as a director; to consider approval of prior issues of securities; and to consider any other business brought forward in accordance with the company's constitution or the law.
Immuron Limited reported preliminary earnings results for the year ended June 30, 2009. For the period, the company reported pre tax loss and loss after tax of AUD 2,550,000 or AUD 0.0187 per share on total revenue of AUD 550,900 as compared to pre tax loss of AUD 3,204,200, loss after tax of AUD 2,935,800 or AUD 0.0279 per share on total revenue of AUD 319,400 for the same period last year. Negative operating cash flow was AUD 2,072,100 as compared to AUD 2,074,500 for the same period last year.
IMROY Competitors
| Company | Last | Change | |
| No competitor information is available for IMROY. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | IMROY | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 14.8x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 29.0x |
|
|
IMROY |
||
IMROY transactions
| Type Date |
Target |
|
Private Placement
September 1, 2009 |
-- |